was successfully added to your cart.

Category

Announcements

Rxight Is Now An Affiliate In The IGNITE Network

By | Announcements, Pharmacogenetic Testing, Pharmacogenomics, Precision Medicine | No Comments

Rxight Pharmacogenetics has become an affiliate member of the NIH-funded effort, IGNITE (Implementing GeNomics In pracTicE). IGNITE is a network dedicated to supporting and advancing the use of genetic information across clinical and diverse healthcare settings. It is comprised of a series of projects aiming to enhance translation of validated actionable genomic information into clinical settings and decision making, and includes educational initiatives for patients and providers. IGNITE is poised to have a significant impact on the acceleration of genomic information into medical practice, and Rxight Pharmacogenetics is proud to be a member of this step forward in clinical care.

Stanford University Appoints Dr. Teri Klein as Professor of Biomedical Data Science

By | Announcements | No Comments

PharmGKB has announced that the Stanford Provost has appointed Dr. Teri Klein as a Professor of Biomedical Data Science.  The appointment is effective March 1 2017 and is a testament to Dr Klein’s academic contributions and leadership in data science and pharmacogenomics.
 
In addition to her post at Stanford, Dr. Klein serves as the Director and Co-Principal Investigator for PharmGKB, the globally recognized and NIH funded resource for clinical pharmacogenetics information, and she is one of the co-founders, leaders and the Co-Principal Investigator of the Clinical Pharmacogenetics Implementation Consortium (CPIC), a shared project between PharmGKB and the Pharmacogenomics Research Network.  PharmGKB curates the worldwide pharmacogenetics data and CPIC provides the clinical guidance to help implement pharmacogenetics into clinical practice.
 

A Leader in Data Science and Pharmacogenomics

 
Dr. Klein’s research interests include pharmacogenetics, computational biology, and bioinformatics. She previously served Associate Adjunct Professor at the University of California at San Francisco. Dr. Klein received her undergraduate degree in Chemistry and Biology in 1980, from the University of California at Santa Cruz. In 1987, Dr. Klein completed her Ph.D. at the University of California at San Francisco, in Medical Information Sciences.
 
Her studies provide an “integrated knowledge base concerning variation in human genetics and how it can lead to variation in our response to drugs, the stability of the collagen triple helix, and the relationship and prediction of lethal mutations for the genetic collagenous disease Osteogenesis imperfecta,” according to the PharmGKB announcement.
 

Key Consultant for MD Labs and Rxight® Pharmacogenetic Testing

 
Additionally, Dr. Klein serves as the Chief Scientific Advisor for MD Labs and the Rxight® Pharmacogenetic Program. In this capacity, Dr. Klein significantly enhances the team’s scientific and clinical abilities as we bring this novel medication therapy program to the retail pharmacy and hospital markets.
 
Developed by MD Labs, Rxight® provides genetic medication therapy guidance for over 200 medications, and includes a Personalized Medication Review® with a Rxight® certified pharmacist. Rxight® offers healthcare providers a way to better understand their individual patient’s responses to prescription and over-the-counter medications, and reduces the risk of adverse drug reactions.   The MD Labs CLIA-Certified Rxight® Pharmacogenetics Program helps prescribers incorporate an individual’s genetic profile to make better and more informed medication therapy decisions.

fruth promotions

Fruth Pharmacy Announces New Hires and Promotions

By | Announcements | No Comments

Fruth announced two promotions (Drew Massey, John Galvin) and a new a director of pharmacy administration (Andy Becker).
 

Drew Massey, who worked with clinical services, will now be responsible for the pharmacists and pharmacy support staff of all locations. John Galvin will be in charge of VP operations and Andy Becker will be working with Drew Massey to manager pharmacy operations.

 

Vardenafil

ABOUT RXIGHT®

Escitalopram

FIND A PHARMACY

Esomeprazole

CONTACT US TODAY

Economic Support for Broadening Pharmacists’ Clinical Role in Laboratory Testing

By | Announcements, Provider | No Comments

Kudos to Timmons and Norris for their paper on the economic support for broadening pharmacists’ clinical role, especially as it relates to laboratory testing: CLIA Waiver Pharmacy Growth: How Does Broadening Scope of Practice Affect the Pharmacist Labor Market?

 

Pharmacists have an important role in the healthcare field. Their functions and responsibilities range from dispensing medications to performing Medication Therapy Management sessions (MTMs). In most states, pharmacists will also collaborate with physicians and provide care for their patients, which frees up time for physicians, brings business to the pharmacy and most importantly ensures the highest quality of health care that a patient can receive. Sometimes that also includes ordering a lab test at the pharmacy when necessary.

 

With a reported reduction in Primary Care Physicians in the near future and with many pharmacies already ordering lab tests on site, it makes sense to expand the role of the pharmacist to include ordering pharmacogenetic tests for those patients that could benefit from it. Since pharmacists are the experts in drug-drug and drug-gene interactions (and are now being taught pharmacogenetics as part of their PharmD education), this is something that would be a natural fit for them. Burdening the physicians for an authorization of a simple cheek swab is not only inefficient, but could also lead to the patient not getting access to a pharmacogenetic test and potentially being on the wrong medication or wrong dosage. Significant time and money could be saved and better health outcomes could be achieved, by allowing pharmacists to order a pharmacogenetic test.

 
With all of these factors taken into consideration, there is a strong case for allowing pharmacists to order pharmacogenetic testing when the processes are in place to mitigate risks to the patient. Such mitigating factors would include a pharmacogenetic counseling session between the patient and pharmacist, alerting prescribers up-front that their patient has chosen PGx testing, and communicating genetic implications as it relates to medication therapy to all relevant prescribers.
 
Denis Grizelj
Co-Founder MD Labs

Vardenafil

ABOUT RXIGHT®

Escitalopram

FIND A PHARMACY

Esomeprazole

CONTACT US TODAY

Related Post

Rxight® Featured in Pharmacy Times Magazine

By | Announcements, Provider | No Comments

The Role of Pharmacogenetics in Precision Medicine. An overview of the science of pharmacogenetics and discussion of the clinical utility of PGx testing in obviating the prevalence of medication non-response and adverse effects as determined by individual variation in genetically mediated response to medications. Li Gong, PhD; Michelle Whirl-Carrillo, PhD; and Teri E, Klein, PhD.

Related Post

MD Labs Appoints Dr. Teri E. Klein of Stanford as a Consultant for its Rxight® Pharmacogenetics Program

By | Announcements | No Comments

PharmGKB Director to Enhance MD Labs’ Scientific and Clinical Research

 

MD Labs is proud to appoint of Dr. Teri E. Klein of Stanford University, PharmGKB and the Clinical Pharmacogenetics Implementation Consortium (CPIC) as a consultant for its Rxight pharmacogenetics. Dr. Klein’s addition to the Rxight pharmacogenetics team as a consultant will enhance the team’s scientific and clinical abilities as we bring this novel medication therapy program to the retail pharmacy market.

 

Dr. Klein received her undergraduate degree in Chemistry and Biology in 1980, from the University of California at Santa Cruz. In 1987, Dr. Klein completed her Ph.D. at the University of California at San Francisco, in Medical Information Sciences.

 

While consulting for MD Labs, Dr. Klein remains a Senior Research Scientist in Stanford’s Department of Genetics, as well as the Director and Co-Principal Investigator for PharmGKB, the globally recognized and NIH funded resource for clinical pharmacogenetics information. Prior to her position at PharmGKB, Dr. Klein was an Associate Adjunct Professor at the University of California at San Francisco. Her research interests include pharmacogenetics, computational biology, and bioinformatics.

 

Dr. Klein is one of the co-founders and leaders of CPIC. Working collaboratively, PharmGKB curates the worldwide pharmacogenetics data and CPIC provides the clinical guidance to help implement pharmacogenetics into clinical practice.

 

Dr. Klein’s research involves studies of an integrated knowledge base concerning variation in human genetics and how it can lead to variation in our response to drugs, the stability of the collagen triple helix, and the relationship and prediction of lethal mutations for the genetic collagenous disease Osteogenesis imperfecta.

 

Developed by MD Labs, Rxight® provides genetic medication therapy guidance for over 210 medications, and includes a Personalized Medication Review with a Rxight certified pharmacist. Rxight® offers healthcare providers a way to better understand their individual patient’s responses to prescription and over the counter
medication, and reduces the risk of adverse drug reactions, which on average claim 106,000 deaths per year, according to research by the Food and Drug Administration.

 

The MD Labs CLIA-Certified Rxight® Pharmacogenetics Test covers over 200 prescription and OTC medications, and as such allows prescribers to incorporate an individual’s genetic profile to make better and more informed medication therapy decisions.

Related Post

Welcome to Precision Medicine and Rxight®

By | Announcements | No Comments

 

Upon surveying the applications of precision medicine in the practice of medication therapies and noting various ways the process could be improved, we set out to change the world of medicine as we know it today, by introducing the Rxight® (pronounced “right”) pharmacogenetic test. While precision pharmacogenetic medication tailoring has been around for several years, it’s accessibility, affordability, application of findings and lack of public awareness have prohibited it from being widely used. In the meantime, millions of people are being prescribed ineffective medications, some of which are downright dangerous to them because of their genetic predispositions.

 

We are taking the most modern science and technology available and not only making it more affordable, but integrating it into an effective and useful model involving a partnership between pharmacists and prescribers. Our Rxight® genetic test covers over 200 OTC and Rx medications and includes a PMR® (Personalized Medication Review®) with a pharmacist trained in pharmacogenetics. This insures that your test results will be fully understood and used to optimize your medication therapy not only for today, but also for the rest of your life.

 

Thank you for learning more about Rxight® PGx Testing.

 

-MD Labs

Vardenafil

ABOUT RXIGHT®

Escitalopram

FIND A PHARMACY

Esomeprazole

CONTACT US TODAY

[REVIEW_SNIPPET]